A federal court has permanently barred California from enforcing the Proposition 65 cancer warning for diethanolamine (DEA) in cosmetics and personal care products. For compliance teams, this is a rare event: a binding legal change already in force that removes a specific enforcement exposure overnight. But the Prop 65 DEA warning injunction is narrower than it first appears, and treating it as a blanket "all clear" would introduce real audit risk. This guide explains exactly what the injunction does, what it does not touch, and how to document the change so it survives internal audit and any future reversal.

Book a compliance risk assessment to map your DEA exposure across products, jurisdictionCanada Toxic Substances Regulations 2025 (SOR/2025-270): What Manufacturers Must Knows, and BOMs before you adjust any labels.

Key Takeaways

📌 A June 24, 2026 federal injunction bars California's Attorney General from enforcing the Prop 65 DEA cancer warning in cosmetics and personal care products only.

⚠️ DEA is not delisted. This restrains enforcement of one warning in one product category. The listing (effective June 22, 2012) remains in force.

⚠️ The order is silent on private "bounty-hunter" enforcers, who bring most Prop 65 actions. Whether they are bound is unresolved.

🏭 Non-cosmetic DEA exposures (industrial, institutional, cleaning products) are outside the order and remain fully enforceable.

📌 A separate OEHHA rulemaking is proposing a dermal DEA safe-harbor level, now 5.8 µg/day, alongside a 54 µg/day level for 1-bromopropane.

⏳ The injunction is reversible. Because it was entered on stipulation, the Attorney General reserves the right to move to dissolve it under Rule 60(b).

📄 The correct compliance posture is to document this as an injunction against enforcement, not a delisting, and to treat it as a monitored status.

What the Injunction Actually Does

On June 24, 2026, the U.S. District Court for the Eastern District of California entered a final judgment and permanent injunction in The Personal Care Products Council v. Bonta, No. 2:26-cv-00682 (E.D. Cal.). The order permanently enjoins Attorney General Rob Bonta, his officers, employees, and agents, and all those acting in privity or concert with them, from filing or prosecuting new Prop 65 suits demanding a cancer warning for DEA in cosmetics and personal care products.

The court declared that, based on the current state of the science, the Prop 65 cancer warning for DEA cannot be enforced consistent with the First Amendment. You can read the primary regulatory record on OEHHA's Proposition 65 program page, and Certivo's Prop 65 framework overview provides the broader compliance context.

What the Injunction Does Not Do

The relief is deliberately limited. Compliance teams that manage chemical and hazmat compliance should treat the following distinctions as controlling.

Because the listing itself stands, the warning obligation is only restrained by enforcement, not eliminated by regulation. That legal distinction is what determines your documentation approach, covered below. OEHHA's official chemical listing notice confirms the June 22, 2012 listing date, and Certivo's guide to Prop 65 compliance for brands explains how listing decisions ripple through supplier data.

Prop 65 DEA warning injunction scope for cosmetics versus industrial products

Click on image to view full

Why the Private-Enforcer Question Still Matters

The vast majority of Prop 65 enforcement actions are brought not by the Attorney General but by private plaintiffs acting in the public interest under Health and Safety Code Section 25249.7(d). The injunction binds the Attorney General and those in privity or concert with him. It does not clearly reach independent private enforcers who file their own actions.

For teams practicing continuous compliance monitoring and audit readiness, this is the decisive operational point. Where risk tolerance is low, retaining existing DEA warnings on cosmetics SKUs remains defensible until courts clarify whether private enforcers are bound. Certivo's proactive risk management use case shows how to hold a monitored position rather than a binary one.

The Separate DEA and 1-BP Safe-Harbor Rulemaking

Independent of the injunction, OEHHA is proposing new No Significant Risk Levels (NSRLs) under Title 27 California Code of Regulations Section 25705(b). This is a two-substance action, not a DEA-only one, and it remains directly relevant to DEA exposures that fall outside the injunction.

The original notice issued August 22, 2025. The June 10, 2026 Notice of Modification revised the DEA dermal figure to reflect an updated dermal absorption factor. Notably, the comment period was extended in June 2026 at the request of the Personal Care Products Council, the same plaintiff that obtained the injunction. As of publication, the rulemaking is pending, with no final adoption. Track it under OEHHA docket 21723, not any internal ticket ID. See the official OEHHA rulemaking notice and the August 2025 NSRL notice. Certivo's materials and environmental compliance solution helps teams manage threshold changes like these across BOMs.

A Pattern of First Amendment Limits on Prop 65 Warnings

This is the fourth successful First Amendment challenge in a developing line, and the escalation is notable: here the Attorney General stipulated to judgment rather than litigating the merits.

The trend matters for regulatory intelligence and horizon scanning. Where the science linking a listed chemical to cancer is genuinely disputed, compelled Prop 65 warnings face growing judicial scrutiny. Certivo's analysis of the Prop 65 bisphenol class review tracks a parallel emerging exposure.

Industries and Products Affected

🏭 Cosmetics and personal care manufacturers, importers, and retailers using DEA or DEA-derived ingredients, most commonly cocamide DEA surfactants in shampoos, soaps, bubble baths, shower gels, conditioners, and hair dyes.

🏭 Any organization managing the high volume of DEA notices of violation in the cosmetics category. That specific enforcement exposure is now restrained.

🏭 Manufacturers of industrial, institutional, or cleaning products containing DEA. These are not covered by the order. The warning requirement remains enforceable, and the pending dermal NSRL is directly relevant.

Cosmetics brands navigating overlapping ingredient bans can review Certivo's coverage of global cosmetics regulatory shifts and the consumer goods industry page for adjacent obligations.

Documentation and Audit-Readiness Implications

For a compliance engineer, the label decision is only half the task. The other half is defensible documentation. This change will surface in several audit contexts, and each expects a different level of evidence.

• Internal audits will test whether the label decision has a documented, current legal basis.

• Customer audits driven by OEMs and retailers will ask why a warning was removed and expect the injunction, not an assumption, on file.

• Regulatory inspections and market surveillance expect the listing status to be tracked accurately.

• Certification audits under quality systems expect version-controlled records of the decision.

The safest posture is point-in-time evidence: a time-stamped record showing who changed the DEA treatment, when, on what authority (the injunction), and with an explicit note that this is an enforcement restraint, not a delisting. Continuous audit-ready documentation and immutable historic-state tracking let you retrieve the exact basis that applied on any given date, which is essential if the Attorney General later moves to dissolve the injunction. No platform makes a program audit-proof. The realistic objective is audit-ready: fewer surprises and faster response. Certivo's BOM-level compliance approach supports exactly this kind of point-in-time retrieval.

Prop 65 DEA injunction versus delisting distinction for audit documentation

Click on image to view full

Recommended Compliance Actions

✓ Flag DEA (CAS 111-42-2) and cocamide DEA (CAS 68603-42-9) in cosmetic and personal care BOMs as no longer carrying Prop 65 cancer-warning enforcement risk while the injunction stands, and document the basis as an injunction against enforcement.

✓ Do not relax DEA warning treatment for non-cosmetic exposures. Industrial, institutional, and cleaning products remain fully enforceable.

✓ Track the 25705(b) rulemaking under OEHHA docket 21723, scoped as both 1-bromopropane (54 µg/day) and DEA dermal (5.8 µg/day).

✓ Build a review trigger for the Rule 60(b) reservation, since the stipulated basis makes this a reversible, monitored status.

✓ Where risk tolerance is low, retain existing DEA warnings on cosmetics SKUs pending clarity on private enforcers.

Certivo's guide to proactive Prop 65 compliance expands on building these triggers into a standing workflow.

How Certivo Supports Prop 65 and Chemical Compliance

Manual Prop 65 tracking across thousands of SKUs and suppliers cannot keep pace with listing changes, injunctions, and shifting safe-harbor levels. Certivo serves as a compliance data backbone that connects substance-level obligations to your bill of materials, so a single event like the DEA injunction can be assessed against every affected product at once.

CORA-powered regulatory intelligence monitors OEHHA notices, rulemakings, and enforcement trends, then maps them to the specific SKUs and suppliers they affect. AI document parsing validates supplier declarations and certificates at scale, and immutable, time-stamped records give compliance engineers the point-in-time evidence that internal and customer audits demand. The result is a shift from reactive, label-by-label compliance toward continuous readiness. Certivo's platform features and chemical compliance solution show how this works across frameworks.

Request a compliance review to see how Certivo maps a single regulatory change to your full product portfolio and supply chain.